share_log

Novo Integrated Sciences | 8-K: Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

Novo Integrated Sciences | 8-K: Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

Novo Integrated Sciences | 8-K：Novo Integrated Sciences公佈2024財年第三季度財務業績
美股SEC公告 ·  2024/07/20 05:06

Moomoo AI 已提取核心訊息

Novo Integrated Sciences reported Q3 FY2024 financial results with revenues of $3.15 million, down 4% YoY from $3.29 million, primarily due to decreased product sales. Despite this, healthcare services revenue increased by 8.1% compared to the same period last year. Operating costs rose 25% to $3.42 million due to inflationary pressures.The company's net loss significantly widened to $13.74 million, an 818% increase from $1.50 million in Q3 FY2023. This substantial increase was mainly attributed to a $6.72 million loss in derivative liability fair value, $2.75 million debt discount amortization, and $1.46 million foreign currency exchange loss. Cash and cash equivalents stood at $1.54 million, with total assets of $35.33 million.In April 2024, the company secured a $6.21 million Securities Purchase Agreement with Streeterville Capital LLC, carrying a 10.9% interest rate and 12-month maturity. The proceeds were partially used to repay existing notes, including a $3.23 million Mast Hill note and an $83,000 First Fire note.
Novo Integrated Sciences reported Q3 FY2024 financial results with revenues of $3.15 million, down 4% YoY from $3.29 million, primarily due to decreased product sales. Despite this, healthcare services revenue increased by 8.1% compared to the same period last year. Operating costs rose 25% to $3.42 million due to inflationary pressures.The company's net loss significantly widened to $13.74 million, an 818% increase from $1.50 million in Q3 FY2023. This substantial increase was mainly attributed to a $6.72 million loss in derivative liability fair value, $2.75 million debt discount amortization, and $1.46 million foreign currency exchange loss. Cash and cash equivalents stood at $1.54 million, with total assets of $35.33 million.In April 2024, the company secured a $6.21 million Securities Purchase Agreement with Streeterville Capital LLC, carrying a 10.9% interest rate and 12-month maturity. The proceeds were partially used to repay existing notes, including a $3.23 million Mast Hill note and an $83,000 First Fire note.
Novo Integrated Sciences發佈了2024財年第三季度的財務結果，營業收入爲315萬美元，同比下降4%，前一年爲329萬美元，這主要是由於產品銷售減少。儘管如此，醫療服務收入與去年同期相比增長了8.1%。由於通貨膨脹壓力，運營成本增長了25%，達到342萬美元。公司的淨虧損大幅擴大至1374萬美元，比2023財年第三季度的150萬美元增加了818%。這種大幅增加主要歸因於672萬美元的衍生負債公允價值損失、275萬美元的債務折扣攤銷和146萬美元的外幣兌換損失。現金及現金等價物爲154萬美元，總資產爲3533萬美元。2024年4月，公司與Streeterville Capital LLC簽署了621萬美元的證券購買協議，利率爲10.9%，期限爲12個月。收益部分用於償還現有的票據，包括323萬美元的Mast Hill票據和83,000美元的First Fire票據。
Novo Integrated Sciences發佈了2024財年第三季度的財務結果，營業收入爲315萬美元，同比下降4%，前一年爲329萬美元，這主要是由於產品銷售減少。儘管如此，醫療服務收入與去年同期相比增長了8.1%。由於通貨膨脹壓力，運營成本增長了25%，達到342萬美元。公司的淨虧損大幅擴大至1374萬美元，比2023財年第三季度的150萬美元增加了818%。這種大幅增加主要歸因於672萬美元的衍生負債公允價值損失、275萬美元的債務折扣攤銷和146萬美元的外幣兌換損失。現金及現金等價物爲154萬美元，總資產爲3533萬美元。2024年4月，公司與Streeterville Capital LLC簽署了621萬美元的證券購買協議，利率爲10.9%，期限爲12個月。收益部分用於償還現有的票據，包括323萬美元的Mast Hill票據和83,000美元的First Fire票據。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    英偉達
    NVDA
    -- 124.920
    特斯拉
    TSLA
    -- 292.980
    Palantir
    PLTR
    -- 84.920
    SoundHound AI
    SOUN
    -- 10.820
    美國超微公司
    AMD
    -- 99.860
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股集體大漲！2025年中國資產前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家機構唱好中國資產。 $阿里巴巴 (BABA.US)$ 、 $京東 (JD.US)$ 、 $富途控股 (FUTU.US)$ 等中概股價格飆升，市場情緒火熱。 🎙️討論： Deepseek 展开
    中國股票的瘋狂反彈暫停了？華爾街仍然對熱門股下注